New reports released on Wednesday have shown that spending on GLP-1 drugs, such as Ozempic and Wegovy, is projected to continue rising in the future. This has caused concerns for the US healthcare system and federal government. According to one study by the American Society of Health-System Pharmacists, GLP-1 treatments were identified as a major driver behind the overall increase in drug spending by health entities, such as pharmacies and hospitals, in the previous year.
In particular, expenditures on Novo Nordisk’s semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, doubled to $38.6 billion in 2023. The second report, conducted by health policy research organization KFF, focused on the impact of the recent approval of Wegovy for preventing cardiovascular complications. Medicare is typically prohibited from covering medications for weight loss purposes but now allows federal payer to cover the drug when prescribed to reduce heart risks. As a result, researchers estimate that Medicare could spend $2.8 billion annually on this single drug. These reports highlight the escalating costs associated with GLP-1 drugs and their potential financial implications for healthcare systems and government payers moving forward.
The upcoming second round of French parliamentary elections is expected to be a close contest…
In the western Indian state of Gujarat, at least seven people have died in a…
Starting on Tuesday, Business Loop 70 in Columbia will be closed for up to 36…
In recent years, airlines have faced increasing competition and pressure to offer unique and memorable…
Yaroslava Mahuchikh from Ukraine set a new world record in high jump during a Diamond…
At the Paris Diamond League, Laura Muir broke the British 1500m record with a time…